行情

UTHR

UTHR

联合治疗
NASDAQ

实时行情|Nasdaq Last Sale

89.57
-1.39
-1.53%
已收盘, 16:11 11/12 EST
开盘
90.71
昨收
90.96
最高
91.15
最低
89.05
成交量
28.20万
成交额
--
52周最高
128.94
52周最低
74.31
市值
39.30亿
市盈率(TTM)
-40.6305
分时
5日
1月
3月
1年
5年

分析师评级

10位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

UTHR 新闻

  • Assessing MannKind's Q3 - What Investors Need To Know
  • Seeking Alpha - Article.2天前
  • Arena Pharmaceuticals' (ARNA) Q3 Loss Widens, Revenues Beat
  • Zacks.4天前
  • Only 1 Number Mattered in Arena Pharmaceuticals' Q3 Results -- and It Was Big
  • MotleyFool.com.5天前
  • Edited Transcript of UTHR earnings conference call or presentation 30-Oct-19 1:00pm GMT
  • Thomson Reuters StreetEvents.11/04 13:49

更多

所属板块

生物技术和医学研究
+0.28%
制药与医学研究
+0.27%

热门股票

名称
价格
涨跌幅

UTHR 简况

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). The Company markets and sells an oncology product in the United States, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of neuroblastoma. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies.
展开

Webull提供United Therapeutics Corporation的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。